BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vector vaccine
Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC) have announced DCGI approval for emergency use authorisation first of its kind intranasal COVID-19 Vaccine to Bharat Biotech.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vector vaccine. It consists of a replication-deficient ChAd vector expressing the stabilized Spike SARS-CoV-2 (Wuhan variant).
DBT’s Autonomous Institute, National Institute of Immunology (NII), New Delhi utilised the “Human Immune Monitoring and T-cell Immunoassay Platform” to examine the vaccine-induced SARS-CoV-2-specific systemic and mucosal cellular immune responses the trial participants. Interactive Research School for Health Affairs (IRSHA), Pune completed the Plaque Reduction Neutralization Assay (PRNT) to quantify the titer of neutralising antibodies for the virus from three trial sites.
Dr Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC speaking on the subject said, “The Department through Mission COVID Suraksha, is committed to the development of safe and efficacious COVID-19 vaccines. BBV154 COVID vaccine is the first intranasal vaccine approved by DCGI for primary immunisation against COVID-19 in the 18+ age group for restricted use in an emergency being developed in the country under Mission COVID Suraksha and adds to our repertoire of COVID-19 vaccine.”